UPDATE: Oppenheimer Raises PT on Medtronic Following Solid FQ4 Sales
May 22, 2013 at 11:28 AM EDT
In a report published Wednesday, Oppenheimer analyst Steven Lichtman raised the price target on Medtronic (NYSE: MDT ) from $52.00 to $57.00, and maintained the Outperform rating. In the report, Oppenheimer noted, “Solid F4Q sales were highlighted by improved performances from US ICD/spine. Excluding these businesses and U.S. pacemakers, the
